These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 29610042)
41. [Herbal drugs: from traditional use to regulation]. Federici E; Multari G; Gallo FR; Palazzino G Ann Ist Super Sanita; 2005; 41(1):49-54. PubMed ID: 16037650 [TBL] [Abstract][Full Text] [Related]
42. History of regulatory requirements for poultry biologics in the United States, 1970s to 1990s. Espeseth DA; Lasher H Avian Dis; 2013 Jun; 57(2):167-71. PubMed ID: 24689169 [TBL] [Abstract][Full Text] [Related]
43. Herbal medicinal products - Evidence and tradition from a historical perspective. Jütte R; Heinrich M; Helmstädter A; Langhorst J; Meng G; Niebling W; Pommerening T; Trampisch HJ J Ethnopharmacol; 2017 Jul; 207():220-225. PubMed ID: 28668645 [TBL] [Abstract][Full Text] [Related]
44. The case for plant-made veterinary immunotherapeutics. Topp E; Irwin R; McAllister T; Lessard M; Joensuu JJ; Kolotilin I; Conrad U; Stöger E; Mor T; Warzecha H; Hall JC; McLean MD; Cox E; Devriendt B; Potter A; Depicker A; Virdi V; Holbrook L; Doshi K; Dussault M; Friendship R; Yarosh O; Yoo HS; MacDonald J; Menassa R Biotechnol Adv; 2016; 34(5):597-604. PubMed ID: 26875776 [TBL] [Abstract][Full Text] [Related]
45. Canadian regulatory requirements for recombinant fish vaccines. Sethi MS; Gifford GA; Samagh BS Dev Biol Stand; 1997; 90():347-53. PubMed ID: 9270863 [TBL] [Abstract][Full Text] [Related]
46. Regulatory considerations for marker vaccines and diagnostic tests in the U.S. Foley PL; Hill RE Biologicals; 2005 Dec; 33(4):253-6. PubMed ID: 16257538 [TBL] [Abstract][Full Text] [Related]
49. New vaccine technologies. Wood DJ Dev Biol (Basel); 2002; 111():285-90. PubMed ID: 12678251 [TBL] [Abstract][Full Text] [Related]
50. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization. Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831 [TBL] [Abstract][Full Text] [Related]
51. Innovations in the veterinary intestinal health field: A patent landscape analysis. Janse MEM; Zinkweg DB; Larsen OFA; van de Burgwal L One Health; 2022 Dec; 15():100419. PubMed ID: 36277087 [TBL] [Abstract][Full Text] [Related]
52. Regulatory considerations for clinical development of cancer vaccines. Heelan BT Hum Vaccin Immunother; 2014; 10(11):3409-14. PubMed ID: 25625933 [TBL] [Abstract][Full Text] [Related]
53. The legislative and regulatory framework governing herbal medicine use and practice in Kenya: a review. Okumu MO; Ochola FO; Onyango AO; Mbaria JM; Gakuya DW; Kanja LW; Kiama SG; Onyango MA Pan Afr Med J; 2017; 28():232. PubMed ID: 29629018 [TBL] [Abstract][Full Text] [Related]
54. Development of a cell-based medicinal product: regulatory structures in the European Union. Gálvez P; Clares B; Hmadcha A; Ruiz A; Soria B Br Med Bull; 2013; 105():85-105. PubMed ID: 23184855 [TBL] [Abstract][Full Text] [Related]
55. Monographs, list entries, public statements. Chinou I J Ethnopharmacol; 2014 Dec; 158 Pt B():458-62. PubMed ID: 25193681 [TBL] [Abstract][Full Text] [Related]
56. Regulatory issues concerning the safety, efficacy and quality of herbal remedies. Rousseaux CG; Schachter H Birth Defects Res B Dev Reprod Toxicol; 2003 Dec; 68(6):505-10. PubMed ID: 14745988 [TBL] [Abstract][Full Text] [Related]
57. An update of antidote availability in veterinary medicine. Post LO; Keller WC Vet Hum Toxicol; 1999 Aug; 41(4):258-61. PubMed ID: 10434385 [TBL] [Abstract][Full Text] [Related]
58. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Gibson GR; Hutkins R; Sanders ME; Prescott SL; Reimer RA; Salminen SJ; Scott K; Stanton C; Swanson KS; Cani PD; Verbeke K; Reid G Nat Rev Gastroenterol Hepatol; 2017 Aug; 14(8):491-502. PubMed ID: 28611480 [TBL] [Abstract][Full Text] [Related]
59. Considerations for rapid development and licencing of conventional and platform technology veterinary vaccines. Francis MJ Avian Pathol; 2022 Apr; 51(2):107-112. PubMed ID: 35201912 [TBL] [Abstract][Full Text] [Related]
60. What are the limitations on the wider therapeutic use of phage? Henein A Bacteriophage; 2013 Apr; 3(2):e24872. PubMed ID: 24228220 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]